BD to move plastic tube business

BD (Franklin Lakes, New Jersey) says that a $25 million expansion will add 100 jobs at the Durham, North Carolina, manufacturing plant where BD makes plastic laboratory pipettes and flasks for drug research. Over the next two years, BD said it will build a 50,000 square-foot addition to the plant that now covers 190,000 square feet and employs 285 at the 120-acre campus in Treyburn Industrial Park north of Durham.

BD, which currently makes plastic lab tubes at its plant in Canaan, Connecticut, plans to move the tube production line to Treyburn.

BD’s labware unit, which employs about 700 worldwide, could have consolidated production of flasks, pipettes and tubes at a plant in Plymouth, England, said William Kozy, BD executive VP. The company said it picked Durham because of the Triangle’s pool of trained labor and proximity to customers in the U.S. and Asia. Also, the Durham campus is suitable for further expansion.

Lenetix Medical gets lab permit in California

Lenetix Medical Screening Laboratory (Mineola, New York) reported that it has been granted a clinical laboratory permit by the State of California. Lenetix is a provider of rapid genetic risk assessment tools and diagnostic tests for clinicians, and is a key partner of Sequenom (San Diego), a company that is developing a portfolio of non-invasive prenatal diagnostics. The notification means that Lenetix is now permitted to receive clinical samples from clients residing in California.

“The opportunity that this permit brings to Lenetix is immeasurable,” said Leonard Kellner, president of Lenetix. “Establishing a presence in California will allow us to build a strong customer base in anticipation of establishing a full-service genetics laboratory serving our clients on the West Coast.”

FONAR in NASDAQ compliance

FONAR (Melville, New York) said it has received notice from NASDAQ that NASDAQ’s listing qualifications panel had found it to be in full compliance with its listing requirements, including its share price, and the post-split price performance of FONAR shares. Consequently, the panel has restored today FONAR’s trading symbol to (FONR) from (FONRD) following its recommended continued listing of the Company’s securities on the NASDAQ Stock Market.

FONAR Chairman, Raymond Damadian, reported that “we are pleased to receive the news of FONAR’s ‘demonstrated compliance with all NASDAQ Marketplace Rules’ and the resulting decision by NASDAQ for continued listing of FONAR on the NASDAQ Stock Market, especially in light of FONAR’s exciting prospects going forward with the myriad of applications for FONAR’s new UPRIGHT™ MR Imaging technology that seem to unfold almost daily.”

Sontra changes stock symbol

Sontra Medical (Franklin, Massachusetts) reported that its common stock is now quoted on the OTC Bulletin Board under the symbol SONT.OB. The Company’s common stock was previously quoted on the “Pink Sheets” under the symbol SONT.PK.

Sontra Medical, a transdermal science company, is developing a non-invasive, continuous transdermal glucose monitor (CTGM) for use in the diabetes and intensive care markets.

Innovative Biosensors reclocates operations

Innovative Biosensors (Rockville, Maryland), makers of ultra-sensitive tests to detect harmful pathogens for both the clinical and biodefense markets, said that it has graduated from the University of Maryland College Park, Technology Advancement Program (TAP) Incubator. It has relocated its operations to the Red Cross’ Jerome Holland Laboratory facility in Rockville, Maryland.

“We are delighted with the progress we have made towards commercialization of the technology. This is due, in part, to the unwavering support of the University of Maryland, the Maryland Technology Enterprise Institute, and the A. James Clark School of Engineering over the past three years,” said Joe Hernandez, President and CEO of IBI. “The larger facility will enable us to expand our research and development programs and scale-up manufacturing to meet upcoming customer needs.”

No Comments